CSL (ASX:CSL) share price struggles despite new government funding

The CSL share price is lower today amid a new initiative to support biotech start-ups.

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in global biotech company CSL Limited (ASX: CSL) are struggling to find range today and are now inching 0.25% lower at $315.28.

Whilst there is no market sensitive information out of the blood plasma specialist's corner today, it released a statement to the media regarding an upcoming venture.

CSL will team up with Melbourne University and The Walter and Eliza Hall Institute of Medical Research (WEHI) to create an incubator and wet space lab for biotech start-ups, with support from the Victorian government.

Here are the details.

Driving world class research

CSL announced today the group has secured funding to create a start-up incubator, with the goal of supporting and growing early-stage Australian biotech companies.

Funding has been secured alongside a contribution from Breakthrough Victoria, the independent investment company administering the Victorian government's $2 billion Breakthrough Victoria Fund. 

The incubator will support start-ups by enabling them to "translate promising medical research into commercial outcomes".

In practical terms, the incubator will take on small biotech companies engaged in early research that want to take their discoveries to the next stage of development.

One factor the incubator wants to address is "skill gaps in translating research into commercial products".

Aside from "state of the art wet lab facilities", the incubator will also provide a range of services including "commercialisation education programs, facilitated access to investors, industry mentoring, and access to service providers".

Speaking on the announcement, CSL's CEO Paul Perreault said:

As one of the world's leading biotechnology companies, CSL is driven by our promise as a patient-focused organisation, so this partnership clearly aligns with our Values and Purpose. We are well positioned to support incubator residents, whose experience often lies purely within the lab, better understand commercial aspects of medicines development that may be foreign or new to them.

Why an incubator?

As CSL puts it, incubators reduce barriers to entry for start-ups. It's all about cost reduction and incubators can offer a 'one-stop shop' by minimising expenditure on things otherwise cost-prohibitive to small companies.

CSL notes start-ups that are incubated have a much higher five-year survival rate and accelerated growth trajectory compared with standalone entities.

Speaking on the announcement, WEHI director Professor Doug Hilton said the collaboration will "help to build a generation of corporate and management-skilled scientists who have the knowledge and confidence to run a successful biomed or biotech company".

The incubator is scheduled to open to start-ups in 2023 and will be able to accommodate up to 40 early-stage companies from around Australia.

CSL share price snapshot

It's been a difficult past 12 months for the CSL share price which has lost 0.09% in that time. However, this year to date it has climbed almost 12% and is up around 7% this past month.

Despite this, over the past 12 months, CSL shares have lagged the benchmark S&P/ASX 200 Index (ASX: XJO).

The  author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A young smiling couple out hiking enjoy a view from the top of the mountains.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors enjoyed a rosy end to the trading week this Friday.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

How these 3 ASX 200 stocks led the charge higher this week

The three top ASX 200 stocks are up 14% to 34% this week.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

These shares are ending the week on a high. But why? Let's find out.

Read more »

A happy girl in a yellow playsuit with a zip gives the thumbs up
BNPL shares

Is this why the Zip share price keeps breaking records?

Zip shareholders have been enjoying a record breaking year. Is this why?

Read more »

A man and a woman sit in front of a laptop looking fascinated and captivated.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile, but positive, day for ASX shares this Thursday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Block, GQG, Neuren, and Sigma shares are racing higher today

These shares are rising on Thursday. But why?

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Brainchip, Cooper Energy, Core Lithium, and Neuren shares are roaring higher today

These shares are having a good time on hump day. But why?

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured a rough day of trading this Tuesday.

Read more »